Further validation showed that NOV and GSTM3 demonstrated robust causal associations with bladder cancer across multiple analytical methods, and molecular docking analysis revealed that these two proteins can bind to estrogen/progestin hormone-regulating drugs. The gene discussed is GSTM3; the disease is urinary bladder carcinoma.